Infliximab induced T lymphocyte apoptosis in Crohn's disease

Journal of Rheumatology

Volumn 32, Issue SUPPL. 74, 2005, Pages 26-30

  Van Den Brande, Jan M H ^a   Hommes, Daan W ^a   Peppelenbosch, Maikel P ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Crohn's disease; Etanercept; Infliximab; Tumor necrosis factor

Indexed keywords

CASPASE 3; ETANERCEPT; FAS LIGAND; INFLIXIMAB; INTERLEUKIN 2; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; BINDING AFFINITY; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CROHN DISEASE; DRUG EFFICACY; GENETIC TRANSFECTION; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; APOPTOSIS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 14944377012     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
3. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94.
4. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999;116:557-65.
5. Itoh J, de La Motte C, Strong SA, Levine AD, Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001;49:35-41.
6. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081-90.
7. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
8. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
9. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
10. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.